Interestingly, in a phase 2 multicenter study, Maude et al. demonstrated that children and young adults with recurrent or refractory B-ALL treated with the CD-19-targeted CAR-T cell product tisagenlecleucel, showed a high overall remission rate of 82% with a durable response up to 12 months (76% OS and 50% event-free survival at 12 months) [10]. Here, CD19 is linked to acute lymphoblastic leukemia.